Establishment Labs (NASDAQ:ESTA) Sets New 52-Week High – Here’s What Happened

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $92.89 and last traded at $92.0310, with a volume of 45215 shares changing hands. The stock had previously closed at $90.62.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ESTA shares. TD Cowen reissued a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Mizuho raised their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday. Citigroup increased their price target on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Finally, BTIG Research reiterated a “buy” rating on shares of Establishment Labs in a research report on Monday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and an average target price of $90.43.

Establishment Labs Stock Performance

The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The firm’s fifty day moving average price is $80.16 and its 200-day moving average price is $71.98. The company has a market cap of $2.72 billion, a P/E ratio of -62.13 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s revenue was up 44.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.70) earnings per share. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director directly owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 255,000 shares of company stock valued at $18,144,896. Company insiders own 9.99% of the company’s stock.

Institutional Investors Weigh In On Establishment Labs

Several large investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after acquiring an additional 9,557 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Establishment Labs during the second quarter worth about $651,000. Nebula Research & Development LLC grew its holdings in shares of Establishment Labs by 27.9% during the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock worth $692,000 after buying an additional 3,538 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in Establishment Labs by 13.3% in the 2nd quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after acquiring an additional 5,668 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.